[go: up one dir, main page]

DE60026704D1 - (S,S)-Reboxetine zur Behandlung chronischer Schmerzen - Google Patents

(S,S)-Reboxetine zur Behandlung chronischer Schmerzen

Info

Publication number
DE60026704D1
DE60026704D1 DE60026704T DE60026704T DE60026704D1 DE 60026704 D1 DE60026704 D1 DE 60026704D1 DE 60026704 T DE60026704 T DE 60026704T DE 60026704 T DE60026704 T DE 60026704T DE 60026704 D1 DE60026704 D1 DE 60026704D1
Authority
DE
Germany
Prior art keywords
reboxetine
treatment
chronic pain
pain
chronic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60026704T
Other languages
English (en)
Other versions
DE60026704T2 (de
Inventor
H Wong
Saeeduddin Ahmed
Clyde Marshall
Robert Mcarthur
P Taylor
Lars Birgerson
Pasquale Cetera
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co LLC
Original Assignee
Pharmacia and Upjohn Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27495506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60026704(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia and Upjohn Co LLC filed Critical Pharmacia and Upjohn Co LLC
Application granted granted Critical
Publication of DE60026704D1 publication Critical patent/DE60026704D1/de
Publication of DE60026704T2 publication Critical patent/DE60026704T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60026704T 1999-07-01 2000-06-22 (S,S)-Reboxetine zur Behandlung chronischer Schmerzen Expired - Lifetime DE60026704T2 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US14196899P 1999-07-01 1999-07-01
US141968P 1999-07-01
US14413199P 1999-07-16 1999-07-16
US144131P 1999-07-16
US15825699P 1999-10-06 1999-10-06
US158256P 1999-10-06
US17038199P 1999-12-13 1999-12-13
US170381P 1999-12-13
PCT/US2000/017256 WO2001001973A2 (en) 1999-07-01 2000-06-22 Highly selective norepinephrine reuptake inhibitors and methods of using the same

Publications (2)

Publication Number Publication Date
DE60026704D1 true DE60026704D1 (de) 2006-05-11
DE60026704T2 DE60026704T2 (de) 2006-10-19

Family

ID=27495506

Family Applications (9)

Application Number Title Priority Date Filing Date
DE60022917T Expired - Fee Related DE60022917T2 (de) 1999-07-01 2000-06-22 Reboxetin zur Behandlung von Migränekopfschmerzen
DE60035232T Expired - Lifetime DE60035232T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von chronischem Müdigkeits-Syndrom
DE60020613T Expired - Lifetime DE60020613T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen
DE60026627T Expired - Fee Related DE60026627T2 (de) 1999-07-01 2000-06-22 Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen
DE60023043T Expired - Lifetime DE60023043T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von Inkontinenz
DE60022692T Expired - Lifetime DE60022692T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
DE60022916T Expired - Fee Related DE60022916T2 (de) 1999-07-01 2000-06-22 Reboxetin zur Behandlung von peripheren Neuropathien
DE60019473T Expired - Lifetime DE60019473T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von peripheren Neuropathien
DE60026704T Expired - Lifetime DE60026704T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetine zur Behandlung chronischer Schmerzen

Family Applications Before (8)

Application Number Title Priority Date Filing Date
DE60022917T Expired - Fee Related DE60022917T2 (de) 1999-07-01 2000-06-22 Reboxetin zur Behandlung von Migränekopfschmerzen
DE60035232T Expired - Lifetime DE60035232T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von chronischem Müdigkeits-Syndrom
DE60020613T Expired - Lifetime DE60020613T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen
DE60026627T Expired - Fee Related DE60026627T2 (de) 1999-07-01 2000-06-22 Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen
DE60023043T Expired - Lifetime DE60023043T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von Inkontinenz
DE60022692T Expired - Lifetime DE60022692T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
DE60022916T Expired - Fee Related DE60022916T2 (de) 1999-07-01 2000-06-22 Reboxetin zur Behandlung von peripheren Neuropathien
DE60019473T Expired - Lifetime DE60019473T2 (de) 1999-07-01 2000-06-22 (S,S)-Reboxetin zur Behandlung von peripheren Neuropathien

Country Status (30)

Country Link
US (18) US6465458B1 (de)
EP (3) EP1196172B1 (de)
JP (3) JP2003503450A (de)
KR (5) KR100948757B1 (de)
CN (5) CN1289090C (de)
AR (1) AR035158A1 (de)
AT (9) ATE305306T1 (de)
AU (2) AU771258B2 (de)
BR (1) BR0012136A (de)
CA (2) CA2375908C (de)
CL (3) CL2008002866A1 (de)
CO (1) CO5190662A1 (de)
CZ (1) CZ299847B6 (de)
DE (9) DE60022917T2 (de)
DK (4) DK1459750T3 (de)
EA (6) EA005029B1 (de)
ES (9) ES2247572T3 (de)
GE (1) GEP20094798B (de)
HU (1) HUP0201623A3 (de)
IL (3) IL147246A0 (de)
MX (1) MXPA02000562A (de)
MY (1) MY137348A (de)
NO (4) NO20016406L (de)
NZ (2) NZ515885A (de)
PE (1) PE20010684A1 (de)
PL (1) PL196996B1 (de)
PT (5) PT1459750E (de)
SK (5) SK286667B6 (de)
TW (9) TWI293250B (de)
WO (1) WO2001001973A2 (de)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK286667B6 (sk) * 1999-07-01 2009-03-05 Pharmacia & Upjohn Company Použitie opticky čistého (S,S)-reboxetínu alebo jeho farmaceuticky prijateľnej soli na výrobu lieku na liečenie alebo prevenciu chronického únavového syndrómu
MXPA02005275A (es) * 1999-12-01 2003-02-17 Ucb Sa Derivado de pirrolidinacetamida solo en combinacion para el tratamiento de trastornos del sistema nervioso central.
DK1274430T3 (da) * 2000-04-21 2006-02-13 Pharmacia & Upjohn Co Llc Cabergolin til behandling af fibromyalgi og kronisk trathedssyndrom
CN1418099A (zh) * 2000-04-21 2003-05-14 法玛西雅厄普约翰美国公司 用于治疗肌纤维疼痛和慢性疲劳综合征的精选化合物
EP1333835A1 (de) * 2000-10-31 2003-08-13 Head Explorer A/S Anwendung von selektiven noradrenalin-reuptake-hemmern für die behandlung von spannungskopfschmerzen
SK5422003A3 (en) * 2000-11-15 2003-12-02 Lilly Co Eli Treatment of anxiety disorders
WO2002083141A1 (en) * 2001-04-17 2002-10-24 Pharmacia & Upjohn Company Treatment of fibromyalgia and chronic fatigue syndrome
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US20060167074A1 (en) * 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
ATE338557T1 (de) * 2001-06-19 2006-09-15 Norbert Mueller Verwendung von cox2 inhibitoren zur behandlung von schizophrenia und des ticks
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
PT1455770E (pt) * 2001-11-30 2007-09-06 Lilly Co Eli Uso de inibidores de reabsorção da norepinefrina para o tratamento dos transtornos de tiques.
CN1713900A (zh) * 2001-12-11 2005-12-28 伊莱利利公司 去甲肾上腺素再摄取抑制剂在治疗认知障碍中的应用
US20040102440A1 (en) * 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
AU2003213009A1 (en) * 2002-02-12 2003-09-04 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
EP1499309A4 (de) * 2002-04-24 2008-05-28 Cypress Bioscience Inc Prävention und behandlung von funktionellen somatischen erkrankungen, einschliesslich stressbedingten erkrankungen
KR20110043664A (ko) 2002-05-17 2011-04-27 듀크 유니버시티 비만치료방법
NZ536415A (en) * 2002-05-30 2006-10-27 Neurosearch As Triple monoamine reuptake inhibitors for the treatment of chronic pain
EP1515959B1 (de) * 2002-06-17 2009-08-12 Pfizer Italia S.r.l. Pharmazeutische salze von reboxetin
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
MY136318A (en) * 2002-07-25 2008-09-30 Pharmacia Corp Sustained-release tablet composition
EP1530476A1 (de) * 2002-08-14 2005-05-18 Pharmacia & Upjohn Company LLC Verwendung von reboxetin zur behandlung von hitzewallungen
ATE413882T1 (de) 2002-08-23 2008-11-15 Lilly Co Eli 2-(phenylthiomethyl)- morpholin-derivate zur verwendung als selektive norepinephrin- wiederaufnahme-inhibitoren
GB0219687D0 (en) 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
ES2264028T3 (es) 2002-08-23 2006-12-16 Eli Lilly And Company Derivados de bencilmorfolina.
EP1558231A4 (de) * 2002-10-03 2010-09-08 Cypress Bioscience Inc Dosiseskalation und geteilte tagesdosis von antidepressiva zurbehandlung von neurologischen erkrankungen
US20040152710A1 (en) * 2002-10-15 2004-08-05 Deecher Darlene Coleman Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US7345096B2 (en) * 2002-10-15 2008-03-18 Wyeth Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US20040180879A1 (en) * 2002-10-15 2004-09-16 Deecher Darlene Coleman Novel method of treating vasomotor symptoms
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
MXPA05007379A (es) * 2003-01-13 2006-02-10 Dynogen Pharmaceuticals Inc Metodo para tratar nauseas, vomito, esfuerzo por vomitar o cualquier combinacion de los mismos.
AU2004204825B2 (en) * 2003-01-13 2007-07-19 Dynogen Pharmaceuticals, Inc. Method of treating functional bowel disorders
DE602004007225T2 (de) * 2003-04-04 2008-03-06 Dynogen Pharmaceuticals Inc., Waltham Methode zur behandlung von erkrankungen der unteren harnwege
CA2522708C (en) 2003-04-29 2013-05-28 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2004100929A1 (en) 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
WO2004105690A2 (en) * 2003-05-23 2004-12-09 Cypress Bioscience, Inc. Treatment of chronic pain associated with drug or radiation therapy
GB0319793D0 (en) * 2003-08-22 2003-09-24 Lilly Co Eli Pyridinylmorpholine derivatives
EP1660065A2 (de) * 2003-08-27 2006-05-31 Eli Lilly And Company Behandlung von pervasiven entwicklungsstörungen mit norepinephrin-wiederaufnahme-hemmern
WO2005025561A1 (en) * 2003-09-04 2005-03-24 Synergia Pharma, Inc. Compositions and methods for orthostatic intolerance
WO2005025675A1 (en) * 2003-09-12 2005-03-24 Pfizer Limited Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
US7524846B2 (en) 2003-10-14 2009-04-28 Wyeth Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use
US7531543B2 (en) 2003-10-14 2009-05-12 Wyeth Phenylpiperazine cycloalkanol derivatives and methods of their use
US20050130987A1 (en) * 2003-10-14 2005-06-16 Wyeth Methods of treating vasomotor symptoms
US7419980B2 (en) 2003-10-14 2008-09-02 Wyeth Fused-aryl and heteroaryl derivatives and methods of their use
US7365076B2 (en) 2003-10-14 2008-04-29 Wyeth Substituted aryl cycloalkanol derivatives and methods of their use
US7402698B2 (en) 2003-10-14 2008-07-22 Wyeth Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use
US7491723B2 (en) 2003-10-14 2009-02-17 Wyeth Alkanol and cycloalkanol-amine derivatives and methods of their use
US7550485B2 (en) 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
CA2548304A1 (en) * 2003-12-12 2005-07-07 Eli Lilly And Company Selective norepinephrine reuptake inhibitors for the treatment of hot flashes, impulse control disorders and personality change due to a general medical condition
WO2005066144A1 (en) * 2003-12-23 2005-07-21 Eli Lilly And Company Morpholine derivatives as norepinephrine reuptake inhibitors
US7517899B2 (en) * 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
US7414052B2 (en) 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
KR100871272B1 (ko) * 2004-04-30 2008-11-28 화이자 인코포레이티드 모폴린 화합물
BRPI0510453A (pt) * 2004-04-30 2007-10-30 Warner Lambert Co composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
AU2005256944A1 (en) * 2004-06-09 2006-01-05 Pfizer Inc. Use of reboxetine for the treatment of pain
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
US20090227562A1 (en) * 2004-08-10 2009-09-10 Pfizer Inc. Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor
PT1789021E (pt) 2004-08-13 2011-12-22 Boehringer Ingelheim Int Formulação de comprimidos de libertação prolongada contendo pramipexole ou um seu sal farmaceuticamente aceitável
AU2005290980A1 (en) * 2004-10-01 2006-04-13 Neurocure Ltd Use of pharmaceutical compositions of lofepramine for the treatment of ADHD, CFS, FM and depression
WO2006105117A2 (en) * 2005-03-28 2006-10-05 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
ES2761812T3 (es) 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
US20070253994A1 (en) * 2006-04-28 2007-11-01 Medtronic, Inc. Intraspinal Drug Delivery Methods and Devices To Alleviate Chronic Pelvic Pain
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
ES2383768T3 (es) * 2006-06-28 2012-06-26 Chelsea Therapeutics Inc. Composiciones farmacéuticas que comprenden droxidopa
AU2007319472B2 (en) 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
EP2134335B1 (de) 2007-03-09 2014-04-23 Chelsea Therapeutics, Inc. Droxidopa und pharmazeutische zusammensetzung davon zur behandlung von fibromyalgie
WO2008122019A1 (en) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
RU2469715C2 (ru) * 2007-04-30 2012-12-20 Адолор Корпорейшн Композиции (-)-e-10-oh-nt и способы их синтеза и применения
AU2008248382B2 (en) * 2007-05-07 2013-07-18 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
US20090233957A1 (en) * 2008-02-19 2009-09-17 Adolor Corporation (-)-beloxepin and methods for its synthesis and use
US20090233959A1 (en) * 2008-02-19 2009-09-17 Adolor Corporation Beloxepin and analogs for the treatment of pain
US8940315B2 (en) 2008-04-18 2015-01-27 Medtronic, Inc. Benzodiazepine formulation in a polyorthoester carrier
US8956642B2 (en) 2008-04-18 2015-02-17 Medtronic, Inc. Bupivacaine formulation in a polyorthoester carrier
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
WO2010011811A2 (en) 2008-07-24 2010-01-28 Theravance, Inc. 3-(phenoxyphenylmethyl)pyrrolidine compounds
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
WO2010044016A1 (en) * 2008-10-17 2010-04-22 Pfizer Limited Novel uses for esreboxetine and racemic reboxetine
EP2419405A1 (de) * 2009-04-15 2012-02-22 Theravance, Inc. 3-(phenoxypyrrolidin-3-ylmethyl)heteroaryl-, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl- und 3-(heteroarylpyrrolidin-3-ylmethoxy)heterarylverbindungen
NZ597433A (en) * 2009-07-13 2013-12-20 Theravance Inc 3-phenoxymethylpyrrolidine compounds
ES2495366T3 (es) 2009-07-21 2014-09-17 Theravance, Inc. Compuestos de 3-fenoximetilpirrolidina
EP2523557B1 (de) 2010-01-11 2019-09-25 Nalpropion Pharmaceuticals, Inc. Verfahren zur bereitstellung einer gewichtsverlusttherapie für patienten mit schweren depressionen
ES2533434T3 (es) 2010-10-11 2015-04-10 Theravance Biopharma R&D Ip, Llc Inhibidores de la captación de la serotonina
US8501964B2 (en) 2010-12-03 2013-08-06 Theravance, Inc. Serotonin reuptake inhibitors
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤
PT2858640T (pt) 2012-06-06 2020-06-30 Nalpropion Pharmaceuticals Llc Composição para utilização num método de tratamento de excesso de peso e obesidade em doentes com alto risco cardiovascular
US10526280B2 (en) 2014-11-13 2020-01-07 University of Pittsburgh—of the Commonwealth System of Higher Education (2-amino-4-(arylamino)phenyl carbamates
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
WO2021113163A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
EP3693020A1 (de) * 2019-02-08 2020-08-12 Burmaster International Group GmbH Kaliumangereicherte topische formulierungen zur schmerzlinderung und schlafhilfe
IL293536A (en) * 2019-12-03 2022-08-01 Axsome Therapeutics Inc Use of reboxetine to treat disease states in the nervous system

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4465458A (en) * 1980-03-19 1984-08-14 Matsushita Electric Industrial Co., Ltd. Apparatus for burning liquid fuel equipped with heating-type fuel vaporizer
GB8419683D0 (en) 1984-08-02 1984-09-05 Erba Farmitalia 3-substituted derivatives of 1-amino-2-hydroxy-propane
GB2167407B (en) * 1984-11-22 1988-05-11 Erba Farmitalia Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
US4596807A (en) 1985-03-26 1986-06-24 Serotonin Industries Of Charleston Method and compositions for controlling pain, depression and sedation
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
PH30083A (en) 1991-02-25 1996-12-27 Lilly Co Eli Treatment of lower urinary tract disorders
US5281624A (en) 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5192751A (en) 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence
TW344661B (en) 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
IL111786A0 (en) 1993-12-01 1995-01-24 Max Planck Gesellschaft Methods of promoting the survival and differentiation of subclasses of cholinergic and serotonergic neurons using fibroblast growth factor-5
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
ZA958725B (en) 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
AU2587297A (en) 1996-03-25 1997-10-17 Eli Lilly And Company Method for treating pain
NZ332039A (en) 1996-03-25 2000-06-23 Lilly Co Eli Method for treating pain using olanzapine and NSAIDs
US5914333A (en) * 1996-07-31 1999-06-22 Novo Nordisk A/S Treatment of psychotic disorders
US20020015713A1 (en) * 1996-10-24 2002-02-07 Murdock Robert W. Methods and transdermal compositions for pain relief
US6572880B2 (en) 1996-10-24 2003-06-03 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US6290986B1 (en) 1996-10-24 2001-09-18 Pharmaceutical Applications Associates, Llc Method and composition for transdermal administration of pharmacologic agents
US6479074B2 (en) 1996-10-24 2002-11-12 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
EP0856312B1 (de) 1996-11-27 1998-10-14 Dr. R. Pfleger Chemische Fabrik GmbH Verwendung von Trospiumchlorid zur Herstellung eines Arzneimittels zur Behandlung von Blasenkrankheiten
KR20000057548A (ko) 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
JP2002503224A (ja) 1997-04-11 2002-01-29 エリ リリー アンド カンパニー 疼痛を処置するための組成物
AU5155198A (en) 1997-08-28 1999-03-22 Robert Murdock Method and composition for transdermal administration of pharmacologic agent
US5942530A (en) 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain
US6622036B1 (en) * 2000-02-09 2003-09-16 Cns Response Method for classifying and treating physiologic brain imbalances using quantitative EEG
UA56257C2 (uk) 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
UA57107C2 (uk) * 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Спосіб лікування розладу поведінки
WO1999015177A1 (en) * 1997-09-23 1999-04-01 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
CA2306233A1 (en) 1997-10-17 1999-04-29 Eli Lilly And Company Potentiation of pharmaceuticals
PT1069900E (pt) * 1998-04-09 2005-10-31 Pharmacia & Upjohn Co Llc Novos tratamentos para disturbios nervosos
US6586427B2 (en) * 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
IT1305322B1 (it) * 1998-04-23 2001-05-04 Pharmacia & Upjohn Spa Uso di reboxetina per il trattamento di disturbi nervosi
IL139211A0 (en) * 1998-05-08 2001-11-25 Upjohn Co New drug combinations of a n.a.r.i., preferably reboxetine, and pindolol
EP1093348A4 (de) 1998-06-29 2003-07-16 Pharmaceuticals Applic Asociat Verfahren und transdermale substanzen zur schmerzlinderung
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
SK286667B6 (sk) * 1999-07-01 2009-03-05 Pharmacia & Upjohn Company Použitie opticky čistého (S,S)-reboxetínu alebo jeho farmaceuticky prijateľnej soli na výrobu lieku na liečenie alebo prevenciu chronického únavového syndrómu
GB2355191A (en) * 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
SE9904750D0 (sv) 1999-12-23 1999-12-23 Pharmacia & Upjohn Ab New formulation, use and method
MXPA02008183A (es) * 2000-02-24 2002-11-29 Upjohn Co Combinaciones de farmacos novedosos.
US20050096349A1 (en) * 2003-11-03 2005-05-05 University Of Florida Methods to prevent or ameliorate medication-, procedure-or stress-induced cognitive and speech dysfunction and methods to optimize cognitive and speech functioning

Also Published As

Publication number Publication date
CN1660108A (zh) 2005-08-31
KR100948757B1 (ko) 2010-03-23
US20030040464A1 (en) 2003-02-27
TW200914027A (en) 2009-04-01
DE60022692T2 (de) 2006-06-22
ES2242175T3 (es) 2005-11-01
KR20020015363A (ko) 2002-02-27
US7241762B2 (en) 2007-07-10
EA008381B1 (ru) 2007-04-27
AU771258B2 (en) 2004-03-18
US20020128173A1 (en) 2002-09-12
PT1459748E (pt) 2005-08-31
TW200922594A (en) 2009-06-01
CL2008002867A1 (es) 2009-01-09
PT1459751E (pt) 2005-11-30
ATE292971T1 (de) 2005-04-15
KR100935277B1 (ko) 2010-01-06
DE60022917D1 (de) 2006-02-09
DE60019473T2 (de) 2006-02-23
ES2239311T3 (es) 2005-09-16
WO2001001973A8 (en) 2001-05-17
ATE305788T1 (de) 2005-10-15
ES2258010T3 (es) 2006-08-16
DE60026704T2 (de) 2006-10-19
PE20010684A1 (es) 2001-06-24
EA200400589A1 (ru) 2004-12-30
DE60023043T2 (de) 2006-06-14
GEP20094798B (en) 2009-10-26
EA200801805A1 (ru) 2008-12-30
DE60022916T2 (de) 2006-07-06
DK1459750T3 (da) 2005-08-15
ES2247572T3 (es) 2006-03-01
JP2003503450A (ja) 2003-01-28
CN1660109A (zh) 2005-08-31
JP2006143749A (ja) 2006-06-08
AU2004202096B2 (en) 2005-10-20
US7317011B2 (en) 2008-01-08
US7338953B2 (en) 2008-03-04
EP2090312A1 (de) 2009-08-19
CN1205935C (zh) 2005-06-15
SK286104B6 (sk) 2008-03-05
SK19382001A3 (sk) 2002-07-02
NZ515885A (en) 2004-08-27
DK1459749T3 (da) 2006-01-09
ES2246487T3 (es) 2006-02-16
KR20090087134A (ko) 2009-08-14
NO20091168L (no) 2002-02-19
EA011094B1 (ru) 2008-12-30
ATE305306T1 (de) 2005-10-15
TWI298255B (en) 2008-07-01
ATE364386T1 (de) 2007-07-15
CO5190662A1 (es) 2002-08-29
BR0012136A (pt) 2002-06-11
US20060142289A1 (en) 2006-06-29
US6610690B2 (en) 2003-08-26
US20060135521A1 (en) 2006-06-22
TW200607509A (en) 2006-03-01
DE60022916D1 (de) 2006-02-09
TW200920378A (en) 2009-05-16
SK286667B6 (sk) 2009-03-05
US20040147614A1 (en) 2004-07-29
US20080103145A1 (en) 2008-05-01
TW200607512A (en) 2006-03-01
ES2246488T3 (es) 2006-02-16
DE60035232T2 (de) 2008-02-14
PT1459750E (pt) 2005-08-31
MXPA02000562A (es) 2002-07-02
US20090247528A1 (en) 2009-10-01
CN1660110A (zh) 2005-08-31
DE60026627D1 (de) 2006-05-04
DK1196172T3 (da) 2006-06-19
EP2087892A3 (de) 2009-09-30
DE60022692D1 (de) 2005-10-20
ES2258251T3 (es) 2006-08-16
HUP0201623A2 (en) 2002-09-28
DE60022917T2 (de) 2006-06-29
EA005029B1 (ru) 2004-10-28
PL196996B1 (pl) 2008-02-29
US20080103146A1 (en) 2008-05-01
ATE296634T1 (de) 2005-06-15
EA200501496A1 (ru) 2006-06-30
CN1379672A (zh) 2002-11-13
DE60026627T2 (de) 2007-02-01
AU5633700A (en) 2001-01-22
CZ299847B6 (cs) 2008-12-10
TWI293250B (en) 2008-02-11
WO2001001973A2 (en) 2001-01-11
DE60023043D1 (de) 2006-02-16
EA200700232A1 (ru) 2007-06-29
EP1196172A2 (de) 2002-04-17
TW200407146A (en) 2004-05-16
EP2087892A2 (de) 2009-08-12
US6703389B2 (en) 2004-03-09
PT1196172E (pt) 2006-05-31
DK1632234T3 (da) 2007-09-17
SK286669B6 (sk) 2009-03-05
KR100717660B1 (ko) 2007-05-15
ATE304358T1 (de) 2005-09-15
PL352252A1 (en) 2003-08-11
TW200607511A (en) 2006-03-01
DE60019473D1 (de) 2005-05-19
KR20060099544A (ko) 2006-09-19
KR100704319B1 (ko) 2007-04-09
NO20016406L (no) 2002-02-19
US20020086864A1 (en) 2002-07-04
US20040058925A1 (en) 2004-03-25
EP1196172B1 (de) 2006-03-15
CN1660111A (zh) 2005-08-31
DE60035232D1 (de) 2007-07-26
MY137348A (en) 2009-01-30
NO20016406D0 (no) 2001-12-28
US20020061910A1 (en) 2002-05-23
ATE319453T1 (de) 2006-03-15
US7276503B2 (en) 2007-10-02
SK286864B6 (sk) 2009-06-05
CA2375908C (en) 2006-05-30
CL2008002868A1 (es) 2009-01-09
CL2008002866A1 (es) 2009-01-09
ES2285645T3 (es) 2007-11-16
EA006652B1 (ru) 2006-02-24
PT1632234E (pt) 2007-07-09
HK1049630A1 (en) 2003-05-23
EA200801806A1 (ru) 2008-12-30
CZ20014625A3 (cs) 2002-08-14
HUP0201623A3 (en) 2004-12-28
TWI294779B (en) 2008-03-21
KR20050053799A (ko) 2005-06-08
IL147246A0 (en) 2002-08-14
SK286668B6 (sk) 2009-03-05
US6642235B2 (en) 2003-11-04
HK1076723A1 (en) 2006-01-27
JP2006321815A (ja) 2006-11-30
IL187513A0 (en) 2008-06-05
IL187512A0 (en) 2008-06-05
TWI298254B (en) 2008-07-01
US7723334B2 (en) 2010-05-25
CA2375908A1 (en) 2001-01-11
AR035158A1 (es) 2004-05-05
US6465458B1 (en) 2002-10-15
US20060264436A1 (en) 2006-11-23
US20020107249A1 (en) 2002-08-08
US6987107B2 (en) 2006-01-17
CA2643231A1 (en) 2001-01-11
NO20091158L (no) 2002-02-19
ES2246485T3 (es) 2006-02-16
WO2001001973A3 (en) 2002-01-17
AU2004202096A1 (en) 2004-06-10
DE60020613D1 (de) 2005-07-07
DE60020613T2 (de) 2006-03-16
CN1289090C (zh) 2006-12-13
NO20091159L (no) 2002-02-19
NZ533243A (en) 2005-12-23
US20080096890A1 (en) 2008-04-24
TW200607510A (en) 2006-03-01
EA200200111A1 (ru) 2002-06-27
TWI245631B (en) 2005-12-21
ATE320257T1 (de) 2006-04-15
US20060128705A1 (en) 2006-06-15
ATE305307T1 (de) 2005-10-15
US20080103147A1 (en) 2008-05-01
KR20090087135A (ko) 2009-08-14
US20060135520A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
ATE320257T1 (de) (s,s)-reboxetine zur behandlung chronischer schmerzen
IL196301A0 (en) Medicament for the treatment of hapatitis c
DE60113496D1 (de) Verwendung von Glycyrrhizin zur Behandlung von Mastitis.
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
EP1274444A4 (de) Arzneistoffe zur behandlung psychiatrischer oder abusus-bedingter störungen
FI20000863A0 (fi) Uusi hoitomenetelmä
DE60322451D1 (de) 4-Tetrazolyl-4-Phenylpiperidinderivate zur Schmerzbehandlung
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
DE60032884D1 (de) Blutbehandlungssystem
ZA200307475B (en) Carbamate compounds for use in the treatment of pain.
DE60111520D1 (de) Hydroxyphenyl-piperazinyl-methyl-benzamid-derivate zur schmerzbehandlung
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
ATE299371T1 (de) Antikonvulsiva zur behandlung von autismus
DE60005566D1 (de) Pyranoindole zur glaukombehandlung
IS2153B (is) S-nítrósóþíól til meðferðar við blóðrásartruflunum
ATE261965T1 (de) Bispidin-derivate zur behandlung von herzarrhythmien
ATE259809T1 (de) Bispidin-derivate zur behandlung von herzarrhythmien
EP1244467A4 (de) Phospholglyerat-kinase zur behandlung von krankheiten
GB0021652D0 (en) System for the extracorporeal treatment of blood

Legal Events

Date Code Title Description
8364 No opposition during term of opposition